RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > CMC, Preclinical and Clinical Considerations for Biosimilars and Follow-on Biologics

CMC, Preclinical and Clinical Considerations for Biosimilars and Follow-on Biologics

Posted 01 January 2008

As noted in the article "Follow-on Biologics in the EU and US," on page 8 of this issue, biologics are created from living organisms, either naturally or via genetic manipulation (e.g., monoclonal antibodies), or are manufactured from complex building blocks of living organisms (e.g., siRNA, aptamers, etc.). In either case, they demonstrate considerable molecular complexity and heterogeneity, and are more difficult to characterize physicochemically than synthetic chemical entities. These differences are reflected in the regulatory agencies' refusal to adopt the same paradigm for generic biologic drugs as for traditional small molecule products.

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe